Vision loss can be challenging. If you could have a one-time gene therapy that would improve your visual acuity, would you take it? It seems like a no-brainer. That's what…
Rare Community Profiles Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…
The ongoing Phase 2 PAVIA clinical study is evaluating EYP-1901 as a potential therapeutic intervention for people with moderately severe to severe non-proliferative diabetic retinopathy; the DAVIO 2 study is…
There are current approved therapies for people living with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). For example, doctors may prescribe VABYSMO, Lucentis, Beovu, Avastin,…
In late May 2023, clinical-stage biotechnology company AiViva Biopharma Inc. ("AiViva") shared via news release that the company had launched a Phase 1 clinical study evaluating AIV007 for diabetic…
An announcement from the drug company Genentech highlights the results of a recent study which demonstrated that the drug faricimab-svoa (marketed at Vabysmo) was able to dry retinal fluid more…
At first, the round black dots that Carmen saw spattered across the bathroom sink were frustrating, but not concerning. Since her grandchildren were staying with her, Carmen assumed that something…
In an article for WebMD, Marilyn Gentile discusses her experience with age-related macular degeneration. She had cataract surgery at 70 years old and just days later she had a central…
According to a story from hopkinsmedicine.org, a study evaluating data from 106 patients living with wet age-related macular degeneration found a significant disparity in outcomes when comparing patients that received…
Regeneron Pharmaceuticals has just announced the results from their Phase 2 trial of aflibercept. The trial aimed to compare an 8mg dose of the treatment to a 2mg dose, which…
According to a recent article, a pilot study shows that around 30% of patients with wet age-related macular degeneration might have the ability to stop their eye injection therapy…
On February 7, 2022, Healthline reported that the FDA had approved Vabysmo (faricimab-svoa), an injectable therapy for those with wet age-relate macular degeneration (wAMD) and diabetic macular edema. This approval…
In October 2021, the FDA approved Susvimo (ranibizumab injection) for the treatment of wet age-related macular degeneration. Now, shares WFMZ, Dr. Chin Yee from Georgia Retina has performed the first…
.jpg)
According to a recent article at EverydayHealth.com, wet age-related macular degeneration (wMD) does not have to signify the end of a patient’s career. With developing treatments and tips from specialists,…
The FDA has recently accepted Genentech's Biologics License Application (BLA) under priority review. This application was for faricimab, a bispecific antibody meant to treat ocular disorders, such as wet age-related…
Clinical trials are important tools in determining the safety, efficacy, and tolerability of new therapeutic options. So it is important to learn when patients are dosed, what those dosages are,…
The FDA approved Beovu, a treatment for wet age-related macular degeneration (wAMD), back in October of 2019. Now, not even two years later, there are changes that must be made…
Ocular Therapeutix has announced that they will attend and present at the Angiogenesis, Exudations, and Degeneration 2021 Meeting, which is being held virtually due to the pandemic. They intend to…
This past November, nearly 9,000 attendees showed up for the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. During the meeting, biopharmaceutical company Kodiak Sciences Inc. ("Kodiak") announced that…
As reported in Medical Xpress; Fight for Sight, a charity in the UK dedicated to vision, has an exciting announcement for people with macular diseases: they have just granted funding…
COVID-19 can't stop the American Society of Retina Specialists (ASRS)! Although their meeting needed to be held online this year thanks to the viral pandemic, the ASRS recently ran…
Over the last few days, the American Society of Retina Specialists (ASRS) held their Annual Virtual Meeting; coined "2020 Virtual Sessions," professionals converged online to share insights into ophthalmological…
Despite rigorous testing before pharmaceutical products are introduced to the market, some still present negative side effects. In a discussion on Beovu (brolucizumab), used to treat neovascular macular degeneration…
As reported in Biospace, Adverum Biotechnologies, a gene therapy company focused on clinical stage trials for rare and ocular diseases with unmet needs, has successfully dosed a patient in their…
Unfortunately, there are downsides to a lot of treatments for various diseases, such as price, frequency of doses, and discomfort. Any one of these factors can discourage people from…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
